Flexion Therapeutics Announces Proposed Public Offering of Common Stock
May 20 2020 - 4:01PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it
has commenced an underwritten public offering of $75,000,000 of
shares of its common stock. Flexion also expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of common stock offered in the public offering. All of
the shares in the offering will be sold by Flexion. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC and Credit Suisse
are acting as joint book-running managers for the proposed
offering.
The shares of common stock described above are
being offered pursuant to a shelf registration statement previously
filed with and declared effective by the Securities and Exchange
Commission (SEC). A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and available for free on the SEC's website at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may also be
obtained from: Goldman Sachs & Co. LLC by mail at 200 West
Street, New York, NY 10282, Attention: Prospectus Department, by
telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or Credit Suisse Securities (USA)
LLC, Attention: Prospectus Department, Eleven Madison
Avenue, 3rd Floor, New York, NY 10010, by telephone at
(800) 221-1037, or by email
at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a
biopharmaceutical company focused on the development and
commercialization of novel, local therapies for the treatment of
patients with musculoskeletal conditions, beginning with
osteoarthritis, the most common form of arthritis. The company’s
core values are focus, ingenuity, tenacity, transparency and
fun.
Forward-Looking Statements
This press release contains forward-looking
statements that are based on our current expectations and beliefs.
Statements in this press release regarding matters that are not
historical facts, including, but not limited to, statements
relating to expectations regarding the size, completion and timing
of the proposed public offering, are forward-looking statements.
These forward-looking statements are based on management's
expectations and assumptions as of the date of this press release
and are subject to numerous risks and uncertainties, which could
cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include,
without limitation, risks associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed offering, as well as other risks and uncertainties
described in our filings with the SEC, including under the heading
"Risk Factors" in our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2020 and subsequent filings with the SEC. There can
be no assurance that we will be able to complete the proposed
public offering on the anticipated terms, or at all. The
forward-looking statements in this press release speak only as of
the date of this press release, and we undertake no obligation to
update or revise any of the statements. We caution investors not to
place considerable reliance on the forward-looking statements
contained in this press release.
Contact:
Scott YoungVice President, Corporate Communications &
Investor RelationsT: 781-305-7194syoung@flexiontherapeutics.com
Julie DownsAssociate Director, Corporate Communications &
Investor RelationsT: 781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024